Evidence map›Paper›PMID 41884596›Full record

ArticleBrain communications2026

Sex differences in diffusion-weighted imaging outcomes in autosomal dominant Alzheimer's disease.

Averi Giudicessi, Elouise Koops, Ana Baena, Sergio Alvarez, Monica Vidal, Lusiana Martinez, Nikole A Bonillas Félix, Isabela Gonzalez, Randy Medrano, Catarina Tristão-Pereira and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Averi GiudicessiDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Elouise KoopsDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Ana BaenaGrupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín 050001, Colombia.
Sergio AlvarezDepartment of Radiology, Hospital Pablo Tobon Uribe, Medellín 050001, Colombia.
Monica VidalDepartment of Radiology, Hospital Pablo Tobon Uribe, Medellín 050001, Colombia.
Lusiana MartinezDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Nikole A Bonillas FélixDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Isabela GonzalezDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Randy MedranoDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Catarina Tristão-PereiraDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Vincent MalotauxDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Bing HeDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Clara Vila-CastelarDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Heidi I L JacobsDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.ORCID https://orcid.org/0000-0001-7620-3822
David AguillonGrupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín 050001, Colombia.
Alice Cronin-GolombDepartment of Psychological and Brain Sciences, Boston University, Boston, MA 02215, USA.ORCID https://orcid.org/0000-0001-5699-6204
Yakeel T QuirozDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.

Funding

Tracking the origin of tau pathology: dovetailing (pre-)preclinical biomarker trajectoriesR01AG062559 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Heidi Irma Jacobs · 2019 to 2026
$4.8M
The wandering nerve: gateway to boost Alzheimer's disease related cognitive performanceR01AG068062 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JACOBS, HEIDI IRMA · 2021 to 2025
$4.6M
Resilience to Cognitive Decline and Resistance to Alzheimer's Disease and Related Neurodegenerative Diseases in Individuals from Colombia with Autosomal Dominant DementiasRM1NS132996 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI AGUILLON, DAVID FERNANDO, ARBOLEDA-VELASQUEZ, JOSEPH · 2023 to 2023
$3.8M
Relationship between tau pathology and cognitive impairment in autosomal dominant Alzheimer's diseaseR01AG054671 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2017 to 2021
$3.8M
Locus coeruleus network architecture of Alzheimer's disease vulnerabilityR01AG082006 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Heidi Irma Jacobs, Jorge Sepulcre · 2023 to 2026
$2.7M
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's diseaseRF1AG077627 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI AGUILLON, DAVID FERNANDO, CUELLO, A CLAUDIO · 2022 to 2022
$2.0M
Examining the impact of sex and hormones on the progression of autosomal dominant Alzheimer's diseaseR00AG073452 · NIA · WASHINGTON UNIVERSITY · PI Clara Vila Castelar · 2025 to 2026
$479k
Elevated locus coeruleus metabolism as mechanism driving Alzheimer's disease pathologyR21AG074220 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JACOBS, HEIDI IRMA · 2021 to 2022
$477k
Examining the impact of sex and hormones on the progression of autosomal dominant Alzheimer's diseaseK99AG073452 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI VILA CASTELAR, CLARA · 2022 to 2023
$268k
Examining Sex-Specific Effects on White Matter Integrity and Brain Function in Familial Alzheimer's Disease and Vascular DementiaF31NS134277 · NINDS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI Averi Jordin Giudicessi · 2024 to 2026
$129k
NIA NIH HHS K99 AG073452NIA NIH HHS R00 AG073452NIA NIH HHS R01 AG054671NIA NIH HHS R01 AG062559NIA NIH HHS R01 AG068062NIA NIH HHS R01 AG082006NIA NIH HHS R21 AG074220NIA NIH HHS RF1 AG077627NINDS NIH HHS F31 NS134277NINDS NIH HHS RM1 NS132996
6 · The paper itself

Abstract

Alzheimer's disease is characterized by amyloid-β and tau protein accumulation. Growing evidence suggests that white matter degeneration contributes to disease progression. Despite Alzheimer's disease being more prevalent in women, understanding of sex differences in white matter microstructure across the Alzheimer's disease continuum remains limited. This study investigated sex-specific patterns of white matter integrity in individuals genetically predisposed to autosomal dominant Alzheimer's disease. We analysed data from 63 individuals (30 presenilin-1 glutamic acid to Alanine at codon 280 (

Indexed as

Alzheimer’s diseaseautosomal dominant Alzheimer’s diseasediffusion tensor imagingsex differenceswhite matter microstructure

Identifiers

PMID41884596
PMCPMC13012221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.